Fw: Aminocare A10 and literature

August 6, 2002

I've been on holiday for three weeks so haven't been active that period. But

this I got from the salesman of antineoplastons in the Netherlands. Maybe

interesting for some of you.

It is all about phenyl-acetaat, the main ingredient of Antineoplastons and

Aminocare A-10 from dr. Burzinsky.

RESEARCH / Publications

Wood JC. In vitro and in vivo studies on the antineoplaston properties and

mechanism of action of a NOVEL amino acid analog,

3-phenylacetylamino-2,6-piperidinedione(A10). PhD Dissertation. Medical

College of Georgia, 1991, Augusta.

Copland JA. Antitumor Activity of 3-phenylacetylamino-2,6-piperidinedione(A10)

and its computer modeled analogs.

PhD Dissertation. Medical College of Georgia; 1992; Augusta, Georgia.

Samid D, Hudgins WR, et al. Phenylacetate and derivates: Simple compounds with

Complex Antitumor Activities.

Proceedings of the AACR, April 1994

Samid D., Wells M., Greene ME, Shen, W., Palmer CN, Thibault, A. Peroxisome

Proliferator-activated Receptor Gamma as a Novel Target in Cancer Therapy:

Binding and Activation by an Aromatic Fatty Acid with Clinical Antitumor

Activity. Clin Cancer Res. 6(3):933-41. Mar 2000.

Ozawa T., Lu R.M., Hu L.J., Lamborn K.R., Prados M.D., and Deen D.F.

Radiopetentiation of human brain tumor cells by sodium Phenylacetate. Elsevier,

Cancer Letters, 142 (1999):139-142., Mar 1999.

Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik

ME, Pollack I, Gilbert M, Rankin C, Prados MD. Phase II study of Phenylacetate

in patients with recurrent malignant glimoa: a North American Brain Tumor

Consortium report. J Clin Oncol., 17:984-990, Mar 1999

Sidnell N, Chang B, Yamashiro JM, Wada RK. Transcriptional up-regulation of

retinoic acid receptor b (RAR expression by Phenylacetate in human

neuroblastoma cells. Exp. Cell Res., 239:169-174, 1998.

Liu L., Kulkarni M., Thibault A., Samid D. Down-regulation of Cyclin D1

Expression in Human Glioma Cells by the Differentiation Inducers Phenylacetate

and Phenylbutyrate. Proceedings of the AACR, Mar 1997.

Wada RK, Huang J., Yamashiro J., Shimoda L., Sidell N. Combination Therapy with

Retinoic Acid and Phenylacetate Induces Differentiation and N-myc

Down-regulation in a Resistant Neuroblastoma Cell Line. Proceedings of the AACR,

Mar 1997.

Lu RM, Ozawa T, Hu LJ, Prados MD, Deen DF. In vitro cytotoxicity and

radiopotentiation of Phenylacetate in human brain tumor cells. Proceedings of

the AACR., Vol. 38, Mar 1997.

..

Prasanna P., Thibault A., Liu L., Samid D. Lipid Metabolism as a Target for

Brain Cancer Therapy: Synergistic Activity of Lovastatin and Sodium

Phenylacetate Against Human Glioma Cells. J. Neurochem,. 66: 710-716. 1996.

Thibout, D., Kraemer, M., Di Benedetto, et al. Sodium Phenylacetate (NaPa)

Induces Modifications of the Proliferation, the Adhesion and the Cell Cycle of

Tumoral Epithelial Breast Cells. Anti Cancer Research. 19(3A):2121-6. May-Jun

1999.

Adam L., Crépin M., Israël L. Tumor Growth Inhibition, Apoptosis, and Bcl-2

Down-regulation of MCF-7ras Tumors by Sodium Phenylacetate and Tamoxifen

Combination. Cancer Res., 57:1023-1029. Mar 1997.

Gorospe M., Shack S. Guyton K.Z., Samid D., Holbrook N.J. Up-regulation and

Functional Role of p21Waf1/Cip1 During Growth Arrest of Human Breast Carcinoma

MCF-7 Cells by Phenylacetate. Cell Growth Differ., 7(12): 1609-1615. Dec 1996.

Shack S., A., Liu L., Thibault A., Prasanna P., Samid D. Vulnerability of

Multidrug-resistant Tumor Cells to the Aromatic Fatty Acids Phenylacetate and

Phenylbutyrate. Clin. Cancer Res., 2:865-872. May 1996.

DE, Ochieng J, SL. Phenylacetic acid halides inhibit estrogen

receptor (ER)-postive MCF-7 cells, but not ER-negative breast cancer cells or

normal breast epithelial cells. Anticancer Drug, 7:288-292. 1999

Witzig T.E., Timm M., Stenson M., Kaufmann S.H. Induction of Apoptosis in

Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with

Chemotherapeutic Agents. Clinical Cancer Research 6(2): 681-92. Feb 2000.

Lea M.A., Hodge S.K., and Randolph V.M. Growth regulation and induction of

histone acetylation by 4-phenylbutyrate and structural analogs. Proceedings of

the AACR. Vol. 40, Apr 1999.

Warrell R.P., He L.Z., Richon V, Calleja E., Pandolif P.P., Therapeutic

Targeting of Transcription in Acute Promyelocytic Leukemia by Use of Inhibitor

of Histone Deacetylase. J Natl Cancer Inst., 490(21):1621-5. Nov 1998.

Gore D., Dvorit Samid, and Li-Jun Weng Impact of the Putative

Differentiating Agents Sodium Phenylbutyrate and Sodium Phenylacetate on

Proliferation, Differentiation, and Apoptosis of Primary Neoplastic Myeloid

Cells. Clin Cancer Res., 3:1755-1762. Oct 1997.

Rivero J.A., Adunyah SE, Ceesay KJ. Phenylbutyrate, Sodium Butyrate and

Phenylacetate Affect of the Levels of p34cdc2 kinase and PKC in K562

Erythroleukemic Cells. Proceedings of the AACR, Mar 1996.

..

Cheng Y., Lotan D., Lotan R. Expression of a Novel Retinoic Acid-inducible Gene

(RAIG01) in Various Tumor Cell Lines and its Regulation by Retinoid, Butyrate,

and Phenylacetate. Proceedings of the AACR, Mar 1998.

Hamilton G, Haberl I, Jager W, et al. Phenylacetate and sodium selenite in vitro

increase the cellular damage induced in PC3 prostate cancer cells by

pretreatment with campthotecines. Proceedings of the AACR, 39:527. 1998.

AC, Whittaker A, Thibault A, Samid D. Modulation of radiation response of

human tumor cells by the differentiation inducers, Phenylacetate. Int J Radiat

Biol, 72:211-218. 1997.

Melchoir S, Stone B, Santucci R, Brown L, True L, J, Lange P, Vesella RA.

Differentiation induces Phenylacetate and phenylbutyrate and their effects in

vitro and on the advanced prostate cancer (CaP) xenograft model LuCaP 23.1.

Proceedings of the AACR., Vol. 37, Mar 1996.

Danesi R, Nardini D, Basolo F, Del Tacca M, Samid D, Myers CE. Phenylacetate

inhibits isoprenylation and growth of the androgen-independent LNCaP prostate

cancer cells transfected with the T24 Ha-ras oncogene. Mol. Pharmacol.,

49:972-979, Mar 1996.

Pineau T., Hudgins W., Liu L., Chen L., Sher T., F., Samid D.

Activation of a Human Peroxisome Proliferator-Activated Receptor by the

Antitumor Agent Phenylacetate and its Analogs. Biochemical Pharmacol.,

56:659-667. 1996.

Walls R, Thibault A, Lui L, Wood C, Kozlowski JM, Figg WD, Sampson ML, Elin RJ,

Samid D. The differentiating agent Phenylacetate increases prostate-specific

antigen production by prostate cancer cells. The Prostate; 29:177-182. 1996.

Hudgins W., Shack S., Myers C., Samid D. Cytostatic Activity of Phenylacetate

and Derivatives Against Tumor Cells: Correlation with Lipophilicity and

Inhibition of Protein Prenylation. Biochemical Pharmacol., 50:1273:1279. 1995.

Boudoulas S., Lush RM., McCall N.A., Samid D., E., Figg WD. Plasma Protein

Binding of Phenylacetate and Phenylbutyrate, Two Novel Antineoplastic Agents.

Ther Drug Monit., 18:714-720. Dec 1996..

Agarwal B., Halmos B., Prorvia P., Swaroop P. et al. Sodium Phenylacetate

Inhibits Proliferation and Induces Apoptosis in Intestinal Epithelial Cell by

Mechanisms Other than Inhibition of Isoprenylation. Proceedings of the AACR, Apr

1999.

Melichar B., Ferrandina G., Kudelka AP, et al. Growth Inhibitory Effects of

Aromatic Fatty Acids on Ovarian Tumor Cell Lines. Clin Cancer Res., 4:3069-3076

Dec 1998.

Ferrandina G., Melichar B., Loercher AE, et al. Growth Inhibitory Effects of

Sodium Phenylacetate (NSC3039) on Ovarian Carcenoma Cell in Vitro. Cancer Res.,

57(19): 4309-15. Mar 1997..

on L., Wojciechowicz, D., Brennan, M., Paty, P. Phenylacetate Inhibits

Isoprenoid Biosynthesis and Suppresses Growth of Human Pancreatic Carcinoma.

Surgery, 124 (3):541-50. Sep 1998.

Wick M., Mangold G., Dexter D., Perkins W., Eckhardt G., Von Hoff D. Combination

Drug Study with Sodium Phenylacetate and Gemcitabine Against the MiaPaCa Human

Pancreatic Cancer Xenograft. Proceedings of the AACR, Mar 1997.

Kebebew E., Wong M.G., Siperstein A.E., Duh, Q-Y and , O.H. Phenylacetate

Inhibits Growth and Vascular Endothelial Growth Factor Secretion in Human

Thyroid Carcinoma Cells and Modulates Their Differentiated Function. J Clin

Endocrin Metab. 84(8):2840-7. Aug 1999.

Hommes, F.A. The Assay of Phenylacetic Acid and 4-phenylbutyric Acid in

Physiological Fluids. Clin Chim Acta. 284(1):109-11. Jun 1999.

..

Samid D., Kulkarni M., Liu L., Thibault A. The Nuclear Receptors, PPARa and

PPARg, are Molecular Targets of the Differentiation Inducers Phenylacetate and

Phenylbutyrate. Proceedings of the AACR, Mar 1997.

Samid D, Hidgins WR, Shack S, Liu L, Prasanna P, Myers CE. Phenylacetate and

phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med.

Biol., 400A:501-505, 1997.

DE, Ochjeng J, Gibbs M, et al. Antiprolifeative activity of

Phenylacetate acid dervicatives against MCF-7 cells. Proceedings of the AACR,

Mar 1995.

Hudgins WR, Pineau T, Sher T, Gonzoles F, Myers CE, Samid D. Anticancer activity

of Phenylacetate and related aromatic fatty acids: correlation with

lipophilicity to activate a nuclear receptor. Proceedings of the AACR, Apr

1994..

Berg S., Serabe B., Aleksic A., Bomgaars L., McGuffey L., Dauser R., Durfee J.,

Nuchtern J., Blaney S. Pharmacokinetics and cerebrospinal fluid penetration of

phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother

Pharmacol. 47: 385-390. February 2001.

Gore SD., Baylin SB., Carducci MA., Cameron EE., Gilbert J., CB., Herman

JG. Sequential DNA Methyltransferase and Histone Deacetylase Inhibition to

Re-express Silenced Genes: Pre-Clinical and Early Clinical Modeling. Proceedings

of the AACR. Vol. 42, March 2001.

Lipschutz J.H., Samid D, Cunha G.R. Phenylacetate is an Inhibitor of Prostatic

Growth and Development in Organ Culture. J Urol., 155:1762-1770. May 1999

--------------------------------------------------------------------------------

August 6, 2002